Latest AVIR reports update at 2024-05-14: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Atea Pharmaceuticals AVIR

$ 3.93 0.0%

Atea Pharmaceuticals Financial Statements 2011-2024 | AVIR

Annual Financial Statements Atea Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	361 M	291 M	740 M	902 M	-	-	-	-	-	-	-	-	-
Shares	83.4 M	83.2 M	82.8 M	21.6 M	-	-	-	-	-	-	-	-	-
Historical Prices	4.33	3.49	8.94	41.8	-	-	-	-	-	-	-	-	-
Net Income	-136 M	-116 M	121 M	-10.9 M	-14 M	-9.06 M	-	-	-	-	-	-	-
Revenue	-	-	351 M	48.6 M	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-164 M	-131 M	138 M	-11 M	-14.6 M	-9.48 M	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-164 M	-130 M	138 M	-11 M	-14.6 M	-9.46 M	-	-	-	-	-	-	-
Operating Expenses	164 M	131 M	213 M	59.7 M	14.6 M	9.48 M	-	-	-	-	-	-	-
General and Administrative Expenses	49.9 M	48.7 M	45.8 M	21.6 M	4.44 M	2.8 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Atea Pharmaceuticals

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	83.9 M	83.4 M	83.4 M	83.4 M	83.3 M	83.3 M	83.3 M	83.3 M	83.2 M	83.1 M	82.8 M	82.7 M	82.6 M	82.4 M	10.1 M	10.1 M	10.1 M	10.1 M	10.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-63.2 M	-	-33.1 M	-28.2 M	-35.5 M	-	-8.07 M	-31.3 M	-42.1 M	-	-28.2 M	1.54 M	30.7 M	-	-17.6 M	-9.99 M	-3.99 M	-	-3.63 M	-3.55 M	-2.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	32.8 M	60.4 M	66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-69.8 M	-	-40.8 M	-35.2 M	-41.6 M	-	-16.3 M	-32.3 M	-42.2 M	-	-22.1 M	8.69 M	30.7 M	-	-17.6 M	-10 M	-4.04 M	-	-3.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-69.7 M	-	-	-	-41.5 M	-	-16.1 M	-32.2 M	-42.2 M	-	-22.1 M	8.7 M	30.7 M	-	-17.6 M	-10 M	-4.04 M	-	-3.76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	69.8 M	-	40.8 M	35.2 M	41.6 M	-	16.3 M	32.3 M	42.2 M	-	55 M	51.7 M	35.3 M	-	17.6 M	10 M	4.04 M	-	3.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	12.2 M	-	12.6 M	13.2 M	12.6 M	-	11.4 M	12.4 M	12.5 M	-	11.9 M	11.9 M	8.76 M	-	4.03 M	2.25 M	1.22 M	-	1.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency